The board of ISTA Pharmaceuticals (ISTA +68.1%) confirms that it rejected Valeant...


The board of ISTA Pharmaceuticals (ISTA +68.1%) confirms that it rejected Valeant Pharmaceuticals' (VRX -0.5%) offer of $6.50/share, calling it "grossly inadequate."

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs